Chromatin Regulators as a Guide for Cancer Treatment Choice

The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio- and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators—factors involved in the establishment and maintenance of functional chromatin domains—can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with docetaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel high-responders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. Mol Cancer Ther; 15(7); 1768–77. ©2016 AACR.

[1]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[2]  P. Hurteloup,et al.  Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .

[3]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[4]  C. Plass,et al.  HLTF gene silencing in human colon cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Sullivan,et al.  Centromeres and Kinetochores From Epigenetics to Mitotic Checkpoint Signaling , 2003, Cell.

[6]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[8]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[9]  J. Klijanienko,et al.  Chromatin Assembly Factor-1, a Marker of Clinical Value to Distinguish Quiescent from Proliferating Cells , 2004, Cancer Research.

[10]  Ramón Díaz-Uriarte,et al.  Gene selection and classification of microarray data using random forest , 2006, BMC Bioinformatics.

[11]  Pedro Larrañaga,et al.  A review of feature selection techniques in bioinformatics , 2007, Bioinform..

[12]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[13]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[14]  Renee F Wilson,et al.  Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer , 2008, Annals of Internal Medicine.

[15]  B. Asselain,et al.  Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncology , 2009, EMBO molecular medicine.

[16]  P. Chambon,et al.  SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. , 2009, Molecular biology of the cell.

[17]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[18]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[19]  Nader Pourmand,et al.  NanoStriDE: normalization and differential expression analysis of NanoString nCounter data , 2011, BMC Bioinformatics.

[20]  E. Barillot,et al.  Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer , 2011, The EMBO journal.

[21]  B. Sullivan,et al.  Genomic size of CENP-A domain is proportional to total alpha satellite array size at human centromeres and expands in cancer cells , 2011, Chromosome Research.

[22]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[23]  Howard A. Fine,et al.  Predicting in vitro drug sensitivity using Random Forests , 2011, Bioinform..

[24]  E. Mardis,et al.  A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.

[25]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[26]  H. A. Schreiber,et al.  An epigenetic silencing pathway controlling T helper 2 cell lineage commitment , 2012, Nature.

[27]  Lin Song,et al.  Random generalized linear model: a highly accurate and interpretable ensemble predictor , 2013, BMC Bioinformatics.

[28]  A. Ashworth,et al.  Challenges translating breast cancer gene signatures into the clinic , 2012, Nature Reviews Clinical Oncology.

[29]  L. McIntosh,et al.  Regulation of mitosis and taxane response by Daxx and Rassf1 , 2011, Oncogene.

[30]  M. Sadelain,et al.  Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma , 2012 .

[31]  Xiaohong Liu,et al.  Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts , 2012, Molecular Cancer Therapeutics.

[32]  M. Dowsett,et al.  Biomarkers for the clinical management of breast cancer: International perspective , 2013, International journal of cancer.

[33]  C. Thompson,et al.  Metabolic Modulation of Epigenetics in Gliomas , 2013, Brain pathology.

[34]  A. Valencia,et al.  Subfunctionalization via adaptive evolution influenced by genomic context: the case of histone chaperones ASF1a and ASF1b. , 2013, Molecular biology and evolution.

[35]  R. Martínez-Zaguilán,et al.  Helicase-Like Transcription Factor (Hltf) Regulates G2/M Transition, Wt1/Gata4/Hif-1a Cardiac Transcription Networks, and Collagen Biogenesis , 2013, PloS one.

[36]  Senén Barro,et al.  Do we need hundreds of classifiers to solve real world classification problems? , 2014, J. Mach. Learn. Res..

[37]  G. Almouzni,et al.  Histone chaperones: assisting histone traffic and nucleosome dynamics. , 2014, Annual review of biochemistry.

[38]  S. Clark,et al.  Chromatin remodeler mutations in human cancers: epigenetic implications. , 2014, Epigenomics.

[39]  M. Lupien,et al.  A global assessment of cancer genomic alterations in epigenetic mechanisms , 2014, Epigenetics & Chromatin.

[40]  G. Almouzni,et al.  Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX. , 2014, Molecular cell.

[41]  G. Almouzni,et al.  Histone H3 variants and their chaperones during development and disease: contributing to epigenetic control. , 2014, Annual review of cell and developmental biology.

[42]  Junjiang Fu,et al.  MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. , 2014, Cancer letters.

[43]  G. Almouzni,et al.  The histone variant composition of centromeres is controlled by the pericentric heterochromatin state during the cell cycle , 2014, Journal of Cell Science.

[44]  Ash A. Alizadeh,et al.  Toward understanding and exploiting tumor heterogeneity , 2015, Nature Medicine.

[45]  F. Reyal,et al.  The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma , 2015, Molecular oncology.

[46]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[47]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[48]  L. Wessels,et al.  Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer. , 2015, Cancer research.

[49]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[50]  Parantu K. Shah,et al.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. , 2015, Cancer research.

[51]  O. Delattre,et al.  SWI/SNF chromatin remodeling and human malignancies. , 2015, Annual review of pathology.

[52]  L. Pusztai,et al.  Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.

[53]  C. Sander,et al.  Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. , 2015, DNA repair.

[54]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[55]  L. Pusztai,et al.  Predictive and Prognostic Value of the TauProtein in Breast Cancer. , 2015, Anticancer research.

[56]  J. Downs,et al.  The SWI/SNF chromatin remodelling complex: Its role in maintaining genome stability and preventing tumourigenesis. , 2015, DNA repair.

[57]  F. Parodi,et al.  The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma , 2015, Cell cycle.

[58]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[59]  T. Honjo,et al.  Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability , 2015, Nature Communications.